Phesgo and Tecentriq Performance and Approvals
Roche Group development pipeline
Phase I (50 NMES + 12 Als)
Roche
RG6007
HLA-A2-WT1 x CD3
AML
Columvi (glofitamab)
RG6026
monotherapy + combos
RG6058
tiragolumab combos
RG6076
englumafusp alfa (CD19-4-1BBL)
heme tumors
heme & solid tumors
combos
RG7802
RG7827
RG7828
CHU
cibisatamab + T
solid tumors
RG6026
FAP-4-1BBL monotherapy + combos
Lunsumio monotheraphy + combos
glypican-3 x CD3
solid tumors
tiragolumab + T
heme tumors
tiragolumab +T+ chemo
RG6058
solid tumors
tiragolumab + T
heme tumors
CHU
codrituzumab
HCC
tiragolumab +T
RG6114
RG6156
inavolisib (mPI3K alpha inh)
EGFRvIII x CD3
solid tumors
CHU
CD137 switch antibody
solid tumors
glioblastoma
CHU
RAS inhibitor
solid tumors
RG6107
RG6139
crovalimab
RG6160
cevostamab (FcRH5 x CD3)
r/r multiple myeloma
CHU
SPYK04
solid tumors
RG6180
RG6171
giredestrant (SERD)
solid tumors
SQZ
PBMC vaccine
solid tumors
RG6180
autogene cevumeran + T
solid tumors
RG6107
crovalimab
lupus nephritis
RG6185
belvarafenib (pan-RAF inh) + Cotellic + T
solid tumors
RG6287
aGVHD
RG6357
RG6358
RG62994
tobemstomig (PD1 x LAG3)
autogene cevumeran + pembrolizumab
dirloctogene samoparvovec (SPK-8011)
SPK-8016
ASO factor B
Phase II (23 NMES + 9 Als)
Columvi (glofitamab) + chemo 1L ctDNA high risk DLBCL
NSCLC
NSCLC neoadj-adj
cervical cancer
1L PD-L1+mSCCHN
sickle cell disease
solid tumors
1L melanoma
hemophilia A
hemophilia A with inhibitors to factor VIII
RG6189
FAP-CD40 ± T
solid tumors
RG6315
immunologic disorders
RG6341
RG6194
runimotamab (HER2 x CD3)
BC
RG6421
TMEM16A potentiator
RG6234
forimtamig (GPRC5D x CD3)
multiple myeloma
RG65363
vixarelimab
cystic fibrosis
immunology
RG7854/
ruzotolimod (TLR7 ago [3])/
RG6346/
RG6264
Phesgo OBI
RG6279
eciskafusp alfa (PD1-IL2v) + T
RG6286
HER2+ BC
solid tumors
colorectal cancer
RG7828
Lunsumio
SLE
CHU
anti-HLA-DQ2.5 x gluten peptides
celiac disease
RG6084**
RG6359
RG1662
xalnesiran (siRNA)/ PDL1 LNA
SPK-3006
basmisanil
Dup15q syndrome
CHU
RAY121
immunology
RG6042
tominersen
RG6292
CD25 MAb combos
heme & solid tumors
RG6006
zosurabalpin (Abx MCP)
RG6323
IL15/IL15Ra-Fc + T
solid tumors
RG6319
LepB inhibitor
complicated
RG6330
divarasib (KRAS G12C)
solid tumors
RG6035
BS-CD20 MAb
RG6333
CD19 x CD28 + Columvi (glofitamab)
r/r NHL
RG6091
rugonersen (UBE3A LNA)
RG6344
BRAF inhibitor (3)
solid tumors
RG6163
RG6392
RG6411
RG6433
SHP2i combos
oncology
solid tumors
solid tumors
RG6440
Anti-latent TGF-ẞ1 (SOF10)
solid tumors
RG6512
FIXa x FX
hemophilia
RG6182
RG6289
RG6418*
RG7637
RG6120
MAGLI
selnoflast
bacterial infections
urinary tract infection
multiple sclerosis
Angelman syndrome
psychiatric disorders
multiple sclerosis
Alzheimer's
inflammation
RG6100
semorinemab
RG6102
trontinemab
latent myostatin + Evrysdi
IgA nephropathy
chronic cough
HBV
Pompe disease
Huntington's
Alzheimer's
Alzheimer's
SMA
RG6237
latent myostatin
FSHD
RG6416
bepranemab
Alzheimer's
RG7314
balovaptan
RG7412
crenezumab
post-traumatic stress disorder
familial Alzheimer's healthy pts
RG7816
alogabat (GABA Aa5 PAM)
zifibancimig (VEGF-Ang2 DutaFab)
RG6524
DLL3 x CD3 x CD137
RG65261
RG65382
camonsertib
P-BCMA-ALLO1
solid tumors
solid tumors
multiple myeloma
RG6209
RG6351
RG7921
CHU
psychiatric disorders
nAMD
retinal disease
retinal disease
RVO
RG7906
ralmitaront
RG7935
RG6179
prasinezumab
anti-IL-6
ASD
schizophrenia
Parkinson's
DME
RG62994
ASO factor B
RG6501
OpRegen
RG7446
RG7601
Morpheus platform
Venclexta + azacitidine
solid tumors
r/r MDS
Status as of April 26, 2023
anti-IL-8 recycling antibody
RG-No-Roche/Genentech; CHU - Chugai managed; SQZ - SQZ Biotechnology
managed; 1Repare Therapeutics managed; 2Poseida Therapeutics managed;
³Kiniksa Pharmaceuticals managed; 4IONIS managed; T-Tecentriq; BS-Brain
Shuttle; OBI-On-Body Delivery System; *also developed in Immunology;
**combination platform
Additional Indication (AI)
Oncology/Hematology
Immunology
Infectious Diseases
endometriosis
RG7774
vicasinabin (CB2 receptor agonist)
New Molecular Entity (NME)
geographic atrophy
geographic atrophy
DR
Metabolism
Neuroscience
Ophthalmology
53
OtherView entire presentation